ChristopherRogerKingMDPhD
Radiation Oncology • Santa Monica, CAProfessor of Radiation Oncology (emeritus), UCLA School of Medicine, Private Oncology Consultant
Dr. King is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Ocean Ave.
Santa Monica, CA 90402Phone+1 310-310-3988
Summary
- Dr. Christopher King is a Board Certified Radiation Oncologist in Santa Monica, CA. He received his MD from Boston University, PhD from Yale, Fellowship from Tufts, and has been in practice 27 years. He is experienced in Prostate cancer, GU cancers, and stereotactic body radiotherapy. He has more than 100 peer-reviewed publications.
Clinical Expertise
- Brachytherapy, Genitourinary cancer, Prostate cancer, Stereotactic radiosurgery, Radiotherapy, Radiation oncology, Stereotactic body radiotherapy
Education & Training
Yale-New Haven Medical CenterResidency, Radiation Oncology, 1995 - 1998
Steward Carney HospitalResidency, Internal Medicine, 1994 - 1995
Boston University Medical CenterInternship, Transitional Year, 1993 - 1994
Boston University School of MedicineClass of 1993- Yale UniversityPhD, Astrophysics, 1987
Certifications & Licensure
CA State Medical License 2000 - 2026
MA State Medical License 1999 - 2000- American Board of Radiology Radiation Oncology
Awards, Honors, & Recognition
- SuperDoctors SuperDoctors, 2015-2020
- BestDoctors BestDoctors, 2003-2020
Publications & Presentations
PubMed
- 6 citationsUnderutilization of Androgen Deprivation Therapy with External Beam Radiotherapy in Men with High-grade Prostate Cancer.Chenyang Wang, Ann C. Raldow, Nicholas G. Nickols, Paul L. Nguyen, Daniel E. Spratt
European Urology Oncology. 2021-04-01 - 11 citationsThe intraprostatic immune environment after stereotactic body radiotherapy is dominated by myeloid cells.Nicholas G. Nickols, Ekambaram Ganapathy, Christine Nguyen, Nathanael Kane, Lin Lin
Prostate Cancer and Prostatic Diseases. 2021-03-01 - 7 citationsDosimetric predictors of patient-reported toxicity after prostate stereotactic body radiotherapy: Analysis of full range of the dose-volume histogram using ensemble ma...Xiaoying Pan, Rebecca Levin-Epstein, Jiahao Huang, Dan Ruan, Christopher R. King
Radiotherapy and Oncology. 2020-07-01
Press Mentions
Here’s the CDC’s New Advice for Protecting Yourself Against COVID-19August 11th, 2022
Professional Memberships
- Member
External Links
- Castle Connollyhttps://www.castleconnolly.com/top-doctors/christopher-r-king-radiation-oncology-16cc004955
- SuperDoctorshttps://www.superdoctors.com/california-los-angeles/doctor/Christopher-R-King/52c03d89-42a6-417f-9129-89b7a533c063.html
- UCLA profilehttps://cc.bingj.com/cache.aspx?q=cr+king+ucla+rad+onc&d=4928320517377500&mkt=en-US&setlang=en-US&w=Iu3dYrzZpsfBJCuKp5nfhwezQgzBaFSV
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
